（编辑 姚尧） 证券日报网讯 1月28日，康恩贝在互动平台回答投资者提问时表示，企业"反内卷"的本质在于持续构建 难以替代的核心竞争力。为此，公司系统规划并着力打造四大核心能力：健康领域全链条品牌塑造能 力、前瞻性研发与管线布局能力、全渠道专业合规推广能力、稳定高效供应链能力，以此筑牢发展根基 与竞争壁垒，驱动经济效益与企业价值同步提升。在拓宽营收渠道方面，公司坚持内涵式增长与外延式 扩张双轮驱动。在内涵式增长方面，公司将巩固优势品种品牌如肠炎宁、前列康、至心砃等的领导地 位；挖掘潜力品种如金笛、牛黄上清胶囊、金艾康等系列产品增长机会；洞察市场机会并完善研发布 局，巩固中药大健康的优势并积极布局创新药，寻找新的增长点。在外延式扩张方面，一方面围绕中药 大健康的股权并购，另一方面公司将通过系统化BD快速获取潜力品种，丰富管线。 ...

Core Viewpoint - The company, Kang En Bei, has appointed Ying Xu as the new chairman of its board of directors, effective immediately, marking a significant leadership change within the organization [1][5]. Company Overview - Kang En Bei, founded in 1969, has evolved from a local pharmaceutical factory into one of the largest traditional Chinese medicine companies in Zhejiang Province and ranks among the top in China's traditional medicine industry [3][7]. - The company was listed on the Shanghai Stock Exchange in 2004 and initiated a major brand development project in 2017, which included well-known trademarks such as Kang En Bei, Qian Lie Kang, Zhen Shi Ming, and Tian Bao Ning [3][7]. Leadership Change - Ying Xu, born in 1973 and a graduate of Shenyang Pharmaceutical University, has held various leadership roles in the pharmaceutical industry, including positions at Zhejiang Yingte Pharmaceutical Co., Ltd. and Zhejiang Yingte Group Co., Ltd. [3][7]. - As of the announcement, Ying Xu does not hold any shares in Kang En Bei [3][7]. Business Transformation - Following a mixed-ownership reform in 2020, Kang En Bei transitioned from a private enterprise to a state-controlled company, with the Zhejiang Provincial State-owned Assets Supervision and Administration Commission as its actual controller [4][8]. - The company operates in multiple sectors, including traditional Chinese medicine, chemical medicine, and health consumer products, boasting over ten billion-yuan brands such as Chang Yan Ning and Qian Lie Kang [4][8]. Financial Performance - In the first three quarters of 2025, Kang En Bei reported a revenue of 4.976 billion yuan, reflecting a year-on-year growth of 1.27%, while the net profit attributable to shareholders reached 584 million yuan, up by 12.65% [5][8]. - The Chang Yan Ning series is projected to achieve sales exceeding 1.5 billion yuan in 2024, maintaining its position as the market leader in the domestic retail market for intestinal medications [4][8].

Core Viewpoint - The resignation of Jiang Yi, the chairman of Kang En Bei, has raised market concerns, marking a significant leadership change within the company, which has been undergoing continuous management adjustments since Zhejiang International Trade Group became the actual controller in 2020 [2][3]. Group 1: Leadership Changes - Jiang Yi's resignation comes after a brief tenure of approximately 1 year and 4 months, originally set to end in August 2027, and is officially attributed to "work adjustments" [3][4]. - Jiang Yi's departure coincides with reports of disciplinary reviews of other executives within Zhejiang International Trade Group, suggesting potential internal issues [3][4]. - The company is currently in the process of selecting a new chairman, with an emphasis on finding a successor with a strong medical background [2][10]. Group 2: Business Strategy and Performance - Jiang Yi's leadership was characterized by a strategic shift towards traditional Chinese medicine and digital transformation, aiming to counteract pressures from the generic drug market [7][9]. - Despite a focus on cost reduction, Kang En Bei's financial performance has shown a decline, with a 2.61% drop in revenue to 3.358 billion yuan and a 7.48% decrease in net profit to 353 million yuan in the first half of 2025 [8][9]. - The company's revenue for the third quarter of 2025 showed a slight increase of 1.27% to 4.976 billion yuan, with net profit rising by 12.65% to 584 million yuan, largely due to cost control measures [8][9]. Group 3: Future Outlook - The future direction of Kang En Bei remains uncertain following Jiang Yi's resignation, particularly regarding the continuation or adjustment of the current "Chinese medicine + digitalization" strategy [10][11]. - The new board candidates, Xu Jie and Jin Junli, are expected to bring relevant expertise and experience to the company, with a focus on enhancing decision-making quality and strategic execution [11]. - Investors are keenly observing how Kang En Bei will balance state regulation and market adaptability during this transitional phase, especially in revitalizing its high-margin product lines and realizing the benefits of digital transformation investments [11].

Group 1 - The core point of the article discusses the frequent changes in top management at companies like Kang En Bei, questioning the effectiveness of such changes in boosting performance during challenging times [1][6] - Kang En Bei has recently experienced a wave of executive turnover, with the resignation of Chairman Jiang Yi and board member Jiang Qian, both of whom were expected to serve until August 2027 [2][3] - The company has a history of management changes, with significant shifts occurring since the entry of Zhejiang Guomao Group in 2020, leading to concerns about the stability of its strategic direction [8][9] Group 2 - Kang En Bei's financial performance has stagnated, with revenue figures from 2020 to 2024 showing minimal growth, and the latest quarterly report indicating a slight year-on-year revenue increase of 1.27% [10][11] - The company's revenue breakdown for the first three quarters of 2025 shows that the traditional Chinese medicine segment remains the largest contributor, but sales of key products have not recovered, and the health consumer goods segment is still underperforming [10] - The stock price of Kang En Bei has been in decline, with a reported market value of 11.69 billion yuan, down approximately 80% from its peak [11]

Core Viewpoint - ST HuLuWa faces significant governance issues and financial challenges, including delayed performance disclosures and high executive turnover, which have led to regulatory penalties and a decline in revenue from key product lines [1][2][3]. Governance and Compliance Issues - The company was penalized by the Shanghai Stock Exchange for failing to disclose a performance warning within the required timeframe, with a projected loss of 250 million to 280 million yuan for the 2024 fiscal year [1]. - High executive turnover has been a persistent issue, with the resignation of long-term chairman and general manager Liu Jingping and the brief tenure of his successor Zhang Mingrui [2][3]. - Previous compliance failures included warnings issued to the former vice president for insider trading, highlighting significant internal control weaknesses [3]. Financial Performance and Challenges - ST HuLuWa's revenue from digestive system drugs fell by 56.94% year-on-year, while sales expenses remained high, indicating pressure from both pricing strategies and cost fluctuations in raw materials [1][6]. - The company's sales expenses reached 611 million yuan in 2024, accounting for 43% of its revenue, significantly higher than many industry peers [9]. Market Dynamics and Competition - The pediatric medication market is undergoing significant changes, with public hospitals increasing their market share to 50.1% in 2024, while retail pharmacy shares have fluctuated [6]. - Competitors like Kuihua Pharmaceutical and Jichuan Pharmaceutical are rapidly expanding their market presence through unique products and strategic acquisitions [1][8]. R&D and Innovation - ST HuLuWa has 116 projects in development, including several innovative traditional Chinese medicine products, but faces challenges in maintaining sustainable R&D investment [8][9]. - The company reported a 77.79% increase in R&D expenses in 2024, but this trend reversed sharply in the first quarter of 2025, raising concerns about the continuity of its innovation pipeline [9].